This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

China Diagnostic Reagent Industry Report, 2012-2014

DUBLIN, Ireland, March 26, 2013 /PRNewswire/ --

Research and Markets announces the addition of " China Diagnostic Reagent Industry Report, 2012-2014" to its catalogue.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

China's diagnostic reagent industry has formed a certain market scale and basis, and is marching from the introduction stage to the growth stage. With the continuous growth in China's medical care investment and per capita health care spending, the China's diagnostic reagent market has a promising prospect.

In vitro diagnostic reagents account for more than 90.0% of the output of China's diagnostic reagent industry. In 2011, the market scale of in vitro diagnostic reagents reached about RMB 11.4 billion in China, the industry will maintain a growth rate of 15%-20% in the future, and the market scale will hit RMB 20.8 billion in 2015.

At present, there are only a few integrated in vitro diagnostic reagent enterprises with strong strength in China's diagnostic reagent market, including KHB and Fosun Pharma; other enterprises such as Da An Gene, BioSino, Leadman and Livzon have competitive advantages in specific fields such as biochemical diagnosis, immunodiagnosis, and molecular diagnosis.

Meanwhile, China's in vitro diagnostic reagent industry concentration is low. Among 300-400 enterprises, there are only about 20 enterprises with annual sales of more than RMB 100 million. The enterprises are generally small and have a few product varieties. In 2011, KHB, Da An Gene, BioSino, Leadman only occupied 3.8%, 2.3%, 1.9%, 1.6% of the market respectively. Key Topics Covered:

1. Overview of Diagnostic Reagent Industry 2. China Diagnostic Reagent Industry 2.1 Overview 2.2 Market Structure 2.3 Import and Export 2.3.1 Import 2.3.2 Export 2.4 Competitive Landscape 2.4.1 Biochemical Diagnostic Reagents 2.4.2 Immune Diagnostic Reagents 2.4.3 Molecular Diagnostic Reagents 2.4.4 Integrated In Vitro Diagnostic Reagents 2.5 Profitability 2.6 Entry Barriers 2.6.1 Technical Barriers 2.6.2 Quality and Brand Barriers 2.6.3 Marketing Channel Barriers 2.6.4 Market Access Barriers 3. Development Environment of China Diagnostic Reagent Industry 3.1 Policy Environment 3.1.1 Regulatory Policy 3.1.2 Industry Policy 3.2 Upstream and Downstream Industries 3.2.1 Industrial Chain 3.2.2 Upstream 3.2.3 Downstream 4. Development Forecast of China Diagnostic Reagent Industry 4.1 Overall Forecast 4.1.1 Market Demand Drivers 4.1.2 Market Scale Forecast 4.2 Development Trends of Diagnostic Reagent Industry 4.2.1 Biochemical Diagnosis and Immunodiagnosis Will Still Be the Mainstream 4.2.2 Industry Concentration Will Increase 4.2.3 Enterprises with Complete Product Line Integrating Reagents and Instruments will Win 5. Major Chinese Diagnostic Reagent Enterprises

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,981.66 +21.09 0.12%
S&P 500 1,979.21 +0.87 0.04%
NASDAQ 4,448.0550 -1.5090 -0.03%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs